NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Ovarian cancer (relapsed) - trabectedin - NIE TAG TA222

Ovarian cancer (relapsed) - trabectedin - NIE TAG TA222

1.1 Trabectedin in combination with pegylated liposomal doxorubicin hydrochloride (PLDH) is not recommended for the treatment of women with relapsed platinum-sensitive ovarian cancer.

1.2 Women with relapsed platinum-sensitive ovarian cancer currently receiving trabectedin plus PLDH should have the option to continue treatment until they and their clinicians consider it appropriate to stop.


Site by Devopa
© Copyright 2022 NHS. All rights reserved.